Exhaustive Guide to Fatty Acid Synthesis and Regulation

Biomedical Importance of Fatty Acids

Fatty acids fulfill several critical roles in human physiology and pathology:

• Energy Storage: Fatty acids are stored in the form of triacylglycerols (TAGs). This is the most efficient form of energy storage in the body, providing approximately $9\,kcal/g$.
• Cell Membrane Structure: Phospholipids, which are derived from fatty acids, constitute the lipid bilayer that forms the structural basis of all cell membranes.
• Signaling Molecules: Fatty acids serve as essential precursors for eicosanoids, including prostaglandins, thromboxanes, and leukotrienes. These molecules are key mediators of inflammation and immune responses.
• Lipid Disorders: Abnormalities in fatty acid synthesis are contributing factors to several metabolic conditions, including obesity, type 2 diabetes, non-alcoholic fatty liver disease (NAFLD), and atherosclerosis.
• Cancer Metabolism: Many tumors exhibit an upregulation of de novo fatty acid synthesis to support rapid cell division. Consequently, fatty acid synthase (FAS) has become a significant therapeutic target in oncology.

Overview: De Novo Fatty Acid Synthesis

De novo fatty acid synthesis is the process of creating fatty acids from non-lipid precursors.

• Location: The process occurs in the cytosol (cytoplasm) of the cell.
• Tissues involved: It primarily takes place in the liver, adipose tissue, lactating mammary glands, kidneys, and the brain.
• Primary Site: The LIVER is the main organ for fatty acid synthesis; it subsequently exports the fatty acids as Very Low-Density Lipoprotein (VLDL).
• Timing: Synthesis occurs when carbohydrate intake exceeds the body's immediate energy needs, leading to the conversion of excess glucose into fatty acids.
• Essential Requirements:     * Acetyl CoA: The fundamental building block.     * NADPH: Provides the necessary reducing power.     * ATP: Provides the energy required for the process.     * $CO_2$ and Biotin: Required for the carboxylation steps.     * Fatty Acid Synthase (FAS) complex: The multi-enzyme system that catalyzes the synthesis.

Production of Malonyl CoA: The Committed Step

The conversion of Acetyl CoA into Malonyl CoA is the first and rate-limiting step of fatty acid synthesis.

• The Reaction: Acetyl CoA (in the cytosol) is converted to Malonyl CoA by the enzyme Acetyl CoA Carboxylase (ACC). This reaction requires $CO_2$, ATP, and Biotin.
• Intermediate: Malonyl CoA is a 3-carbon intermediate.
• Significance of this step:     1. Committed Step: It is the "point of no return" in the fatty acid synthesis pathway.     2. Regulation: Acetyl CoA Carboxylase (ACC) is the most important regulatory enzyme in the entire pathway.     3. Two-Carbon Donor: Malonyl CoA provides a 2-carbon unit to the growing fatty acid chain during each condensation cycle by losing a molecule of $CO_2$.     4. Inhibition of $\beta$-Oxidation: Malonyl CoA inhibits carnitine acyltransferase I. This prevents fatty acids from entering the mitochondria for $\beta$-oxidation.
• Clinical/Physiological Importance: Because Malonyl CoA inhibits the breakdown of fatty acids, the cell cannot synthesize and break down fatty acids simultaneously.

Fatty Acid Synthase (FAS) Complex

The FAS complex is a sophisticated multienzyme system that executes the elongation of the fatty acid chain.

• Structure: FAS is a homodimer consisting of two identical polypeptide chains.
• Composition: Each monomeric chain contains six distinct enzyme activities and one Acyl Carrier Protein (ACP).
• Functional Unit: While each monomer contains all required activities, the actual functional unit consists of one-half of one monomer interacting with the complementary half of the other monomer (a "head-to-tail" arrangement). This allows for the simultaneous production of two acyl chains.
• Enzymatic Components and Functions:     1. $\beta$-Ketoacyl-ACP Synthase (KS) (Condensing enzyme): Condenses the acetyl or acyl group with malonyl to form $\beta$-ketoacyl-ACP, releasing $CO_2$.     2. $\beta$-Ketoacyl-ACP Reductase (KR): Performs the first reduction step using NADPH.     3. $\beta$-Hydroxyacyl-ACP Dehydrase (DH): Catalyzes the dehydration step, removing a molecule of $H_2O$.     4. Enoyl-ACP Reductase (ER): Performs the second reduction step using NADPH.     5. Malonyl/Acetyl Transferase (MAT): Responsible for loading the acetyl and malonyl groups onto the ACP.     6. Thioesterase (TE): Releases the finished 16-carbon palmitate from the ACP.     7. Acyl Carrier Protein (ACP): Acts as a central scaffold. It carries intermediates between enzyme active sites via its 4'-phosphopantetheine arm (containing a sulfhydryl -SH group).

NADPH: The Reducing Power for Fatty Acid Synthesis

Each cycle of fatty acid elongation requires two molecules of NADPH for the two reduction steps. The synthesis of a single 16-carbon palmitate molecule requires a total of 14 NADPH molecules.

• Sources of NADPH:     1. Pentose Phosphate Pathway (PPP): This is the MAIN SOURCE. Glucose-6-phosphate is converted to Ribulose-5-phosphate by Glucose-6-phosphate dehydrogenase (G6PD), producing 2 NADPH per glucose molecule. This occurs in the cytosol, providing easy access for lipogenesis.     2. Malic Enzyme (Cytosolic): Catalyzes the reaction: $\text{Malate} + \text{NADP}^+ \rightarrow \text{Pyruvate} + CO_2 + \text{NADPH}$. This link connects the citrate shuttle to NADPH generation.     3. Isocitrate Dehydrogenase (Cytosolic isoform): Provides a minor contribution by converting Isocitrate + $\text{NADP}^+$ into $\alpha$-Ketoglutarate + $CO_2$ + NADPH.
• Clinical Connection: G6PD deficiency (favism) not only leads to hemolytic anemia due to impaired NADPH production but also reduces the cell's capacity for lipogenesis.

Acetyl CoA: The Building Block and the Citrate Shuttle

All carbon atoms in fatty acids are derived from acetyl CoA. However, acetyl CoA is produced primarily in the mitochondria and cannot cross the inner mitochondrial membrane directly.

• Pathway from Glucose to Cytosolic Acetyl CoA:     1. Glycolysis: Glucose is converted to Pyruvate in the cytosol.     2. Mitochondrial Entry: Pyruvate enters the mitochondria and is converted to Acetyl CoA by Pyruvate Dehydrogenase (PDH).     3. Condensation: Acetyl CoA condenses with Oxaloacetate to form Citrate.     4. Transport: Citrate is transported from the mitochondria to the cytosol via the Citrate Shuttle (also known as the Tricarboxylate Transport System).     5. Cleavage: In the cytosol, the enzyme ATP-Citrate Lyase cleaves Citrate back into Acetyl CoA and Oxaloacetate using ATP.
• Result: This process makes Acetyl CoA available in the cytosol for fatty acid synthesis.

The Elongation Cycle and Overall Reaction

Palmitate (C16:0) is the end product of the FAS complex. The process begins with Acetyl CoA and adds two carbons per cycle for a total of seven cycles.

• The Overall Equation for Palmitate Synthesis:$8\,\text{Acetyl CoA} + 7\,\text{ATP} + 14\,\text{NADPH} + 14\,H^+ + H_2O \rightarrow \text{Palmitate (C16)} + 8\,\text{CoA} + 7\,\text{ADP} + 7\,P_i + 14\,\text{NADP}^+$

• Four Steps of Each Elongation Cycle:     1. Step 1: Condensation: Acetyl (or acyl) group + Malonyl-ACP $\rightarrow$ $\beta$-Ketoacyl-ACP + $CO_2$ (Enzyme: $\beta$-Ketoacyl-ACP Synthase).     2. Step 2: 1st Reduction: $\beta$-Ketoacyl-ACP + NADPH + $H^+$ $\rightarrow$ $\beta$-Hydroxyacyl-ACP (Enzyme: $\beta$-Ketoacyl-ACP Reductase).     3. Step 3: Dehydration: $\beta$-Hydroxyacyl-ACP $\rightarrow$ 2,3-Enoyl-ACP + $H_2O$ (Enzyme: $\beta$-Hydroxyacyl-ACP Dehydrase).     4. Step 4: 2nd Reduction: 2,3-Enoyl-ACP + NADPH + $H^+$ $\rightarrow$ Acyl-ACP (now 2 carbons longer) (Enzyme: Enoyl-ACP Reductase).

• Termination: After 7 cycles, the 16-carbon Palmitoyl-ACP is formed. Thioesterase releases the free PALMITATE (C16:0).

Elongation of Fatty Acid Chains in the Endoplasmic Reticulum

While the FAS complex in the cytosol produces only Palmitate, the body requires longer-chain fatty acids.

• Location: Chain elongation systems are located in the Smooth Endoplasmic Reticulum (SER) and, to a minor extent, in the mitochondria.
• Comparison of FAS vs ER Elongation:     * FAS Complex (Cytosol): Produces Palmitate (C16:0); uses Malonyl-ACP as the donor; uses NADPH as the reducing agent; uses a multienzyme complex.     * ER Elongation System (SER): Produces C18, C20, C22, C24, and longer; uses Malonyl CoA (not ACP) as the donor; uses NADPH as the reducing agent; uses enzymes called Elongases (ELOVL1-7).
• Clinical Relevance: ER elongation is essential for creating Very Long-Chain Fatty Acids (VLCFAs) needed for the brain and the skin's barrier function.
• Mitochondrial Elongation: This is a minor pathway typically for chains C14 and below, adding Acetyl CoA rather than Malonyl CoA.

Regulation: Acetyl CoA Carboxylase (ACC)

As the rate-limiting enzyme, ACC is strictly regulated to control fatty acid synthesis.

• Allosteric Activation:     * Citrate: Promotes the polymerization of ACC into its active filamentous form.     * Glutamate and other dicarboxylates: Act as allosteric activators.
• Hormonal Activation:     * Insulin: Promotes dephosphorylation (activation) of ACC via a phosphatase.     * Dietary Influence: A high-carbohydrate diet increases the gene expression (transcription) of ACC.
• Allosteric Inhibition:     * Palmitoyl CoA (long-chain acyl CoA): Provides product/feedback inhibition and causes the depolymerization of ACC into its inactive form.
• Hormonal/Energy Inhibition:     * Glucagon & Epinephrine: Cause phosphorylation (inactivation) of ACC via the cAMP-dependent Protein Kinase A (PKA) pathway.     * AMP-activated Protein Kinase (AMPK): Phosphorylates and inactivates ACC when cellular energy is low (high AMP levels).     * Fasting/Starvation: Decreases the expression of the ACC gene.
• Clinical Link: Metformin, used for Type 2 Diabetes, activates AMPK, which inhibits ACC. This reduces fatty acid synthesis and hepatic lipogenesis, helping to treat fatty liver.

Regulation: Pyruvate Dehydrogenase (PDH)

PDH serves as the gateway reaction, supplying Acetyl CoA for synthesis by converting Pyruvate to Acetyl CoA in the mitochondria.

• Inhibition by Acyl CoA:     * When fatty acids (Acyl CoA) are abundant, PDH Kinase is ACTIVATED.     * PDH Kinase phosphorylates PDH, making it INACTIVE.     * This prevents the unnecessary production of Acetyl CoA when fatty acids are already available (preventing futile cycling).
• Other PDH Kinase Activators: NADH, Acetyl CoA, and ATP (signals of energy abundance).
• Activation of PDH:     * PDH Phosphatase removes the phosphate group to ACTIVATE PDH.     * PDH Phosphatase is activated by $Ca^{2+}$ (during muscle contraction) and Insulin.

Summary of Hormonal Control of Lipogenesis

• Insulin (Fed State): The most important promoter of lipogenesis.     * Activates ACC (dephosphorylation).     * Increases gene expression for FAS, ACC, and G6PD.     * Activates PDH.     * Promotes glucose uptake and glycolysis to provide Acetyl CoA.
• Glucagon/Epinephrine (Fasting/Stress State): Suppress lipogenesis.     * Activate PKA, which phosphorylates and inactivates ACC.     * Inhibit the overall flux toward fatty acid storage.